The Withdrawal of Benztropine Mesylate in Chronic Schizophrenic Patients

1983 ◽  
Vol 143 (6) ◽  
pp. 584-590 ◽  
Author(s):  
Linda A. Baker ◽  
L. Y. Cheng ◽  
I. B. Amara
Keyword(s):  
Placebo Group ◽  
Test Scores ◽  
Drug Group ◽  
Extrapyramidal Symptoms ◽  
Antiparkinsonian Drug ◽  
Double Blind ◽  
Neuroleptic Medication ◽  
Chronic Schizophrenic ◽  
Wechsler Memory Scale ◽  
Schizophrenic Patients

SummaryIn this double-blind, four-week study, 28 chronic schizophrenic patients receiving neuroleptic medication plus the antiparkinsonian drug, benztropine mesylate, were either switched to placebo or maintained on benztropine. Patients withdrawn from benztropine reliably increased their overall scores on the Wechsler Memory Scale in comparison with the drug group. Sub-test scores suggest that deficits in attention and concentration were induced by treatment with benztropine. Psychotio decompensation appeared to develop simultaneously with extrapyramidal symptoms (EPS) in some patients, but only 14.2 per cent of the placebo group experienced extrapyramidal symptoms severe enough to require resumption of benztropine therapy. It is suggested that antiparkinsonian agents should be prescribed only if and when EPS occur.

Effects of Biperiden and Amantadine on Memory in Medicated Chronic Schizophrenic Patients

1995 ◽  
Vol 166 (2) ◽  
pp. 241-243 ◽  
Author(s):  
H. Silver ◽  
N. Geraisy
Keyword(s):  
Retention Test ◽  
Digit Span ◽  
Double Blind ◽  
Logical Memory ◽  
Chronic Schizophrenic ◽  
Wechsler Memory Scale ◽  
Benton Visual Retention Test ◽  
Schizophrenic Patients ◽  
With Memory

BackgroundThe effects on memory of an anticholinergic (biperiden) and a dopaminergic (amantadine) anti-Parkinsonian agent were compared.MethodTwenty-six chronically medicated schizophrenic (DSM–III–R) in-patients received amantadine (200 mg/day) or biperiden (4 mg/day) for two weeks in a double-blind cross-over design.ResultsBiperiden treatment was associated with significantly lower scores on Benton Visual Retention Test (P< 0.003) and the visual subscale of Wechsler Memory Scale (WMS) (P≤ 0.02), with a trend to poorer scores on WMS total (P= 0.086) and the digit span (P= 0.07) and logical memory (P= 0.06) subscales.ConclusionsIn usual clinical doses, biperiden interferes with memory, particularly visual, more than amantadine.

Propranolol in Schizophrenia: A Double Blind, Placebo Controlled Trial of Propranolol as an Adjunct to Neuroleptic Medication

1983 ◽  
Vol 143 (2) ◽  
pp. 151-155 ◽  
Author(s):  
C. R. Pugh ◽  
J. Steinert ◽  
R. G. Priest
Keyword(s):  
Beneficial Effect ◽  
Recent Work ◽  
Controlled Trial ◽  
Pharmacokinetic Interaction ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Neuroleptic Medication ◽  
Chronic Schizophrenic ◽  
Schizophrenic Patients

SummaryA double blind, placebo controlled trial was carried out to examine the contribution of propranolol as an adjunct to neuroleptic medication in the treatment of chronic schizophrenic patients whose florid symptoms had not remitted with neuroleptic medication alone. Propranolol was shown to have a more beneficial effect than placebo, but the results were much less dramatic than those which have been described in previous studies. Recent work has shown that there may be a pharmacokinetic interaction between propranolol and neuroleptics, and this should be considered as one possible explanation of our findings.

A Controlled Trial of Phenothiazine Withdrawal in Chronic Schizophrenic Patients

1976 ◽  
Vol 128 (5) ◽  
pp. 451-455 ◽  
Author(s):  
P. Andrews ◽  
J. N. Hall ◽  
R. P. Snaith
Keyword(s):  
Placebo Group ◽  
Controlled Trial ◽  
Control Group ◽  
Double Blind ◽  
Chronic Schizophrenic ◽  
Active Medication ◽  
Schizophrenic Patients ◽  
Weekly Assessment ◽  
Phenothiazine Drugs

SummaryPhenothiazine drugs were withdrawn from 17 chronic schizophrenic in-patients, with a control group of 14 patients remaining on active medication. The trial was conducted under double blind conditions over a period of 42 weeks with weekly assessment of the patients by ward nurses. Of the placebo group 35 per cent relapsed, relapse being related to the level of previous active medication.

scholarly journals Antidepressant Effects of a Persian Medicine Remedy on Multiple Sclerosis Patients: A Double-Blinded Randomized Clinical Trial

2019 ◽  
Vol 8 ◽  
pp. e1212
Author(s):  
Maryam Adalat ◽  
Mohammad Khalili ◽  
Hormoz Ayromlou ◽  
Sajjad Haririan ◽  
Seyyed Mohammad Bagher Fazljou ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Placebo Group ◽  
Drug Group ◽  
Rate Of Change ◽  
Crocus Sativus ◽  
Depression Symptoms ◽  
Double Blind ◽  
Symptoms Of Depression ◽  
Persian Medicine ◽  
Multiple Sclerosis Patients

Background: Multiple sclerosis (MS), an inflammatory neurodegenerative disease of the central nervous system, is accompanied by some psychiatric disorders, one prominent example of which is depression. The aim of this study was to investigate the effects of a Persian herbal medicine treatment that contains Crocus sativus, Hypericum perforatum, Cinnamon verum, and Vitis vinifera on fatigue and sleep disorders in MS patients. Materials and Methods: A Persian medicine remedy containing C.sativus, H.perforatum, C.verum, and V.vinifera was tested for its ability to improve the symptoms of depression in MS patients. This randomized double-blind clinical study was performed among 52 patients with MS who were allocated to their respective research groups through blocked randomization. The patients were treated for 4 weeks with either the drug or the placebo. To quantify the symptoms of depression, Beck depression inventory (BDI) was used. Results: Forty-six patients completed the study. In the course of the study, as the primary outcome, BDI decreased in the drug group (p=0.000) and the placebo group (p=0.001) significantly, but the rate of change in the drug group was significantly higher than in the placebo group (-13.9 ± 8.6 vs. -3.9 ± 4.3, p=0.000). While analyzing time and treatment effect for BDI, significant decreases in BDI were observed for the drug group, but not in the placebo group (p= 0.001). Conclusion: The present study suggests that Persian medicine remedy treatment in combination with chemical drugs may improve depression symptoms in MS patients. More investigations are needed to discover the exact mechanisms and processes involved. [GMJ.2019;8:e1212]

Psychological Changes in Chronic Schizophrenics Following Differential Activity Programmes: A Repeat Study

1964 ◽  
Vol 110 (465) ◽  
pp. 283-286 ◽  
Author(s):  
Vernon Hamilton
Keyword(s):  
Occupational Therapy ◽  
Test Scores ◽  
Specific Activity ◽  
Therapeutic Approaches ◽  
Flat Rate ◽  
Chronic Schizophrenic ◽  
Chronic Schizophrenics ◽  
Control Situation ◽  
Schizophrenic Patients ◽  
Activity Therapy

The present investigation was carried out in order to check on the reliability of the findings reported in a previous publication by Hamilton and Salmon (1962). In this first experiment objective assessments were made of the effects on male chronic schizophrenic patients of three activity programmes: Industrial Workshop Therapy, Occupational Therapy and a control situation in which patients did not receive any specific activity therapy. The effects of these therapeutic approaches were assessed in terms of test scores and ratings, as well as output and earnings for those patients receiving Workshop Therapy. For patients undergoing Workshop Therapy a separate assessment was made of the effects of payment by result compared with flat-rate payment, and of co-operative work compared with working as individuals. The major findings of this study were that Industrial Workshop Therapy led to greater improvement than Occupational Therapy, that the greatest changes in behaviour occurred while patients were working individually and receiving a weekly flat-rate payment, that the behavioural changes in the Workshop group continued in the second, piecework, phase of the investigation, that piecework payments did not result in greater output than flat-rate payment, and that patients working in small teams compared with patients working as individuals, both under piecework conditions, showed greater all-round improvement on the indices used to measure it.

A double-blind study with ceruletide in chronic schizophrenic patients: Biochemical and clinical results

1986 ◽  
Vol 19 (1) ◽  
pp. 1-7 ◽  
Author(s):  
Margot Albus ◽  
Klaus von Gellhorn ◽  
Ursula Münch ◽  
Dieter Naber ◽  
Manfred Ackenheil
Keyword(s):  
Clinical Results ◽  
Blind Study ◽  
Double Blind Study ◽  
Double Blind ◽  
Chronic Schizophrenic ◽  
Schizophrenic Patients

Gonadotrophin secretion abnormalities in chronic schizophrenia

1982 ◽  
Vol 12 (2) ◽  
pp. 263-273 ◽  
Author(s):  
I. N. Ferrier ◽  
P. M. Cotes ◽  
T. J. Crow ◽  
E. C. Johnstone
Keyword(s):  
Natural History ◽  
Clinical Features ◽  
Anterior Pituitary ◽  
Chronic Schizophrenia ◽  
Neuroleptic Medication ◽  
Acute Schizophrenia ◽  
Chronic Schizophrenic ◽  
Gonadotrophin Secretion ◽  
Schizophrenic Patients ◽  
Lh Secretion

SynopsisLH, FSH, PRL and testosterone were estimated by radioimmunoassay in serial venous samples from 20 male chronic schizophrenic patients, 17 age-matched controls, 3 patients in remission from acute schizophrenia, and in single samples from age–sex matched populations. LH and FSH, but not testosterone or PRL, were significantly reduced in patients with chronic schizophrenia. There was an associated reduction in the frequency, but not amplitude, of LH secretory episodes in patients with chronic schizophrenia. No abnormalities of LH secretion were detected in those patients in remission from acute schizophrenia. Fourteen of the chronic schizophrenic patients were retested at a later date with similar results, except in the case of the few patients who had been started on neuroleptic medication. Some relationships were established between hormonal secretion and the clinical features of these patients. The possible significance of these findings is discussed in the context of the complex control of gonadotrophin secretion from the anterior pituitary and the natural history and nature of chronic schizophrenia.

Sign in / Sign up

Export Citation Format

Share Document